Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering

Core Viewpoint - Tonix Pharmaceuticals Holding Corp. has successfully closed a public offering, raising gross proceeds of $4.0 million, which will be utilized for working capital, general corporate purposes, and preparation for a new drug application for its Tonmya™ product candidate targeting fibromyalgia [1][4]. Group 1: Offering Details - The public offering consisted of 1,199,448 shares of common stock priced at $1.065 per share and pre-funded warrants to purchase up to 2,568,110 shares at $1.064 each, with an exercise price of $0.001 per share [4]. - Dawson James Securities, Inc. acted as the sole placement agent for the offering [5]. - The offering was conducted under an effective shelf registration statement on Form S-3 previously filed with the SEC [6]. Group 2: Company Overview - Tonix is a fully-integrated biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) disorders, with a priority to submit a New Drug Application for Tonmya in the second half of 2024 [13]. - The company has completed two statistically significant Phase 3 studies for Tonmya, which is intended for the management of fibromyalgia [13]. - Tonix's portfolio includes other product candidates targeting acute stress reaction, cocaine intoxication, organ transplant rejection, autoimmunity, and cancer [13].